The Relative Strength (RS) Rating for Gilead Sciences entered a higher percentile Thursday, as it got a lift from 67 to 71.
Can You Really Time The Stock Market?
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the best stocks often have an RS Rating north of 80 as they launch their biggest price moves. See if Gilead Sciences can continue to rebound and hit that benchmark.
Gilead Sciences is working on a flat base with a 121.83 buy point. See if it can break out in heavy trade. Keep in mind that it's a later-stage consolidation, and those are riskier than earlier-stage patterns.
The company showed 0% earnings growth in the latest quarterly report. Revenue gains came in at 2%.
The company earns the No. 37 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and argenx ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
